Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative capecitabine after short-course radiotherapy and TME for stage II/III rectal cancer
NL-OMON20322Active, not recruiting
- Sponsor
- Dutch Colorectal Cancer Group
- Start
- Oct 2004
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in rectal adenocarcinoma and rectal cancer comparing Capecitabine with Observation (2 arms). Primary endpoint: Overall survival. Started Oct 2004; status: active, not recruiting.
02
Drugs
capecitabine
03
Conditions
rectal adenocarcinomarectal cancer
Beyond the preview
Go deeper on NL-OMON20322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20322.